Novartis AG said it will present new data on Multiple Sclerosis or MS treatment at the 65th annual meeting of the American Academy of Neurology or AAN.
It will highlight growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS or RMS. Updates on studies of Gilenya in people with primary-progressive MS or PPMS and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS or SPMS will also be communicated, the company said... Read More - http://www.ms-uk.org/index.cfm/gilenya
Novartis To Present New Data On Multiple Sclerosis Treatment
Novartis To Present New Data On Multiple Sclerosis Treatment
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1913 Views
-
Last post by frodo
-
- 0 Replies
- 1750 Views
-
Last post by frodo
-
- 0 Replies
- 1778 Views
-
Last post by frodo
-
- 1 Replies
- 1933 Views
-
Last post by frodo
-
- 0 Replies
- 1405 Views
-
Last post by frodo
-
- 0 Replies
- 2458 Views
-
Last post by frodo
-
- 0 Replies
- 3810 Views
-
Last post by frodo
-
- 0 Replies
- 2071 Views
-
Last post by NHE
-
- 0 Replies
- 26 Views
-
Last post by frodo